TMED2 and cancer: Shi-Peng, et al.9 (2017) found TMED2 as an oncogene in ovarian cancer, promoting cancer by activating the insulin-like growth factor 2/insulin-like growth factor 1 receptor/phosphoinositide 3-kinase/protein kinase B pathway.